Cat. No.: HY-16995

Pirinixic acid

(Synonyms: Wy-14643)

38 Cited Publications

Customer Review

Based on 38 publication(s) in Google Scholar

Pirinixic acid (Wy-14643) is a potent agonist of PPARα, with EC₅₀s of 0.63 μM, 32 μM for murine PPARα and PPARγ, and 5.0 μM, 60 μM, 35 μM for human PPARα, PPARγ and PPARδ, respectively.

For research use only. We do not sell to patients.

Purity: 99.34%
CAS No.: 50892-23-4
Formula: C₁₄H₁₄ClN₃O₂S
Molecular Weight:323.80

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Pirinixic acid Chemical Structure

CAS No.: 50892-23-4

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (38)
Solvent & Solubility
- In Vitro
- In Vivo
Protocol
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target^[1]

PPARα

0.63 μM (EC₅₀)

PPARγ

32 μM (EC₅₀)

All PPAR Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
COS-7	EC₅₀	39.8 μM Compound: 1, WY-14,643	Agonist activity at wild-type human PPARalpha LBD expressed in COS7 cells after 12 hrs by Dual-Glo luciferase assay Agonist activity at wild-type human PPARalpha LBD expressed in COS7 cells after 12 hrs by Dual-Glo luciferase assay	[PMID: 25022880]
COS-7	EC₅₀	53.7 μM Compound: 1	Transactivation of human PPARgamma LBD expressed in african green monkey Cos7 cells co-transfected with fused GAL4-DBD after 14 hrs by Dual-Glo Luciferase reporter gene assay Transactivation of human PPARgamma LBD expressed in african green monkey Cos7 cells co-transfected with fused GAL4-DBD after 14 hrs by Dual-Glo Luciferase reporter gene assay	[PMID: 20307981]
COS-7	EC₅₀	53.7 μM Compound: 1, WY-14,643	Agonist activity at human PPARgamma LBD expressed in COS7 cells after 12 hrs by Dual-Glo luciferase assay Agonist activity at human PPARgamma LBD expressed in COS7 cells after 12 hrs by Dual-Glo luciferase assay	[PMID: 25022880]
COS-7	IC₅₀	36.3 μM Compound: 1	Activation of human PPARalpha ligand binding domain expressed in COS7 cells by luciferase reporter gene assay Activation of human PPARalpha ligand binding domain expressed in COS7 cells by luciferase reporter gene assay	[PMID: 25037914]
COS-7	IC₅₀	53.7 μM Compound: 1	Activation of human PPARgamma ligand binding domain expressed in COS7 cells by luciferase reporter gene assay Activation of human PPARgamma ligand binding domain expressed in COS7 cells by luciferase reporter gene assay	[PMID: 25037914]
CV-1	EC₅₀	0.13 μM Compound: Wy14643	Transactivation of human PPARalpha expressed in african green monkey CV1 cells by luciferase reporter gene assay Transactivation of human PPARalpha expressed in african green monkey CV1 cells by luciferase reporter gene assay	[PMID: 22579420]
HEK293	EC₅₀	23.33 μM Compound: WY-14643	Agonist activity at human PPARalpha expressed in HEK293 cells cotransfected with PPREx4-TK-luc assessed as activation of luciferase activity measured after 48 hrs by transactivation assay Agonist activity at human PPARalpha expressed in HEK293 cells cotransfected with PPREx4-TK-luc assessed as activation of luciferase activity measured after 48 hrs by transactivation assay	[PMID: 23265844]
HepG2	EC₅₀	0.04 μM Compound: WY-14643	Agonist activity at mouse PPARalpha ligand binding domain expressed in human Hep G2 cells co-transfected with Gal4-DBD by luciferase reporter gene assay Agonist activity at mouse PPARalpha ligand binding domain expressed in human Hep G2 cells co-transfected with Gal4-DBD by luciferase reporter gene assay	[PMID: 19053776]
HepG2	EC₅₀	1.56 μM Compound: Wy 14,643	Transactivation of GAL4-fused human PPARalpha ligand binding domain expressed in HepG2 cells after 20 hrs by luciferase reporter gene assay Transactivation of GAL4-fused human PPARalpha ligand binding domain expressed in HepG2 cells after 20 hrs by luciferase reporter gene assay	[PMID: 23171045]
HepG2	EC₅₀	1.56 μM Compound: Wy-14,643	Agonist activity at human GAL4-PPARalpha ligand binding domain expressed in human HepG2 cells by luciferase reporter gene assay Agonist activity at human GAL4-PPARalpha ligand binding domain expressed in human HepG2 cells by luciferase reporter gene assay	[PMID: 25462281]
HepG2	EC₅₀	1.6 μM Compound: Wy-14,643	Agonist activity at GAL4-tagged human PPARalpha ligand binding domain expressed in HepG2 cells assessed as transactivation after 20 hrs by beta-galactosidase reporter gene assay Agonist activity at GAL4-tagged human PPARalpha ligand binding domain expressed in HepG2 cells assessed as transactivation after 20 hrs by beta-galactosidase reporter gene assay	[PMID: 22341573]
HepG2	EC₅₀	1.6 μM Compound: WY-14643	Agonist activity at human PPARgamma ligand binding domain expressed in human HepG2 cells co-transfected with Gal4 by luciferase reporter gene assay Agonist activity at human PPARgamma ligand binding domain expressed in human HepG2 cells co-transfected with Gal4 by luciferase reporter gene assay	[PMID: 18835719]
HepG2	EC₅₀	1.6 μM Compound: WY-14643	Agonist activity at GAL4-tagged human PPARalpha ligand binding domain expressed in human HepG2 cells assessed as receptor transactivation by luciferase reporter gene assay Agonist activity at GAL4-tagged human PPARalpha ligand binding domain expressed in human HepG2 cells assessed as receptor transactivation by luciferase reporter gene assay	[PMID: 19775169]
HepG2	EC₅₀	1.6 μM Compound: WY-14643	Agonist activity at human GAL4-fused PPARalpha ligand binding domain expressed in HepG2 cells after 20 hrs by luciferase reporter gene transactivation assay Agonist activity at human GAL4-fused PPARalpha ligand binding domain expressed in HepG2 cells after 20 hrs by luciferase reporter gene transactivation assay	[PMID: 22081932]
HepG2	EC₅₀	1.6 μM Compound: WY-14643	Effective concentration against human PPARalpha expressed in HepG2 cells Effective concentration against human PPARalpha expressed in HepG2 cells	[PMID: 16107150]
HepG2	EC₅₀	1.62 μM Compound: Wy-14,643	Agonist activity at GAL4-DNA binding domain fused human PPARalpha ligand binding domain expressed in human HepG2 cells assessed as receptor transactivation incubated for 20 hrs by luciferase reporter gene assay Agonist activity at GAL4-DNA binding domain fused human PPARalpha ligand binding domain expressed in human HepG2 cells assessed as receptor transactivation incubated for 20 hrs by luciferase reporter gene assay	[PMID: 25497132]
HepG2	EC₅₀	1.62 μM Compound: WY-14643	Agonist activity at human PPARalpha ligand binding domain expressed in human Hep G2 cells co-transfected with Gal4-DBD by luciferase reporter gene assay Agonist activity at human PPARalpha ligand binding domain expressed in human Hep G2 cells co-transfected with Gal4-DBD by luciferase reporter gene assay	[PMID: 19053776]
HepG2	EC₅₀	3.46 μM Compound: WY14643	Agonist activity at GAL4-fused PPARalpha (unknown origin) expressed in human HepG2 cells by transactivation assay Agonist activity at GAL4-fused PPARalpha (unknown origin) expressed in human HepG2 cells by transactivation assay	[PMID: 23502212]
HepG2	EC₅₀	4.8 μM Compound: WY-14643	Agonist activity at PPARalpha expressed in human HepG2 cells assessed as induction of receptor transactivation by reporter gene assay relative to control Agonist activity at PPARalpha expressed in human HepG2 cells assessed as induction of receptor transactivation by reporter gene assay relative to control	[PMID: 18625559]
HepG2	EC₅₀	4800 nM Compound: WY-14643	Transactivation of human PPARalpha expressed in human HepG2 cells co-transfected with PPRE3-TK-Luc by luciferase reporter gene assay Transactivation of human PPARalpha expressed in human HepG2 cells co-transfected with PPRE3-TK-Luc by luciferase reporter gene assay	[PMID: 21450468]
HepG2	EC₅₀	7.1 μM Compound: WY14643	Agonist activity at GAL4-fused PPARalpha A454M mutant (unknown origin) expressed in human HepG2 cells by transactivation assay Agonist activity at GAL4-fused PPARalpha A454M mutant (unknown origin) expressed in human HepG2 cells by transactivation assay	[PMID: 23502212]
MCF7	EC₅₀	542 nM Compound: WY-14643	Agonist activity at human PPARalpha expressed in MCF7 cells co-transfected CPTI DR1-type RE after 6 hrs by luciferase reporter gene assay Agonist activity at human PPARalpha expressed in MCF7 cells co-transfected CPTI DR1-type RE after 6 hrs by luciferase reporter gene assay	[PMID: 24936232]
MCF7	EC₅₀	650 nM Compound: WY-14643	Agonist activity at human PPARalpha expressed in MCF7 cells co-transfected CPTI DR1-type RE after 16 hrs by luciferase reporter gene assay Agonist activity at human PPARalpha expressed in MCF7 cells co-transfected CPTI DR1-type RE after 16 hrs by luciferase reporter gene assay	[PMID: 24936232]
U2OS	EC₅₀	12 μM Compound: WY-14643	Agonist activity at human PPARalpha in U2OS cells by transactivation assay Agonist activity at human PPARalpha in U2OS cells by transactivation assay	[PMID: 18329751]
U2OS	EC₅₀	20 μM Compound: WY-14643	Effect on PPARalpha transactivation activity in U2OS cells Effect on PPARalpha transactivation activity in U2OS cells	[PMID: 16300944]

In Vitro

Pirinixic acid (Wy-14643) is an agonist of PPARα, with EC₅₀s of 0.63 μM, 32 μM for murine PPARα and PPARγ, and 5.0 μM, 60 μM, 35 μM for human PPARα, PPARγ and PPARδ, respectively^[1].
Pirinixic acid (Wy-14643; 0, 10, 100 μM) enhances protein expression of PPAR-α in synovial fibroblasts. Pirinixic acid (0, 10, 100 μM) shows inhibitroy effects on NO and PGE2 production in LPS-stimulated synovial fibroblasts. Pirinixic acid also effectively downregulates expression of inflammatory mediators such as VCAM-1, ICAM-1, ET-1, and TF in synovial fibroblasts, blocks LPS-induced NF-kB activation, IkB phosphorylation, and NF-kB nuclear translocation in synovial fibroblasts, but Pirinixic acid shows no effects in PPAR-α silenced cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Pirinixic acid (Wy-14643; 10 mg/kg, i.v.) decreases hepatic injury and lipid peroxidation (MDA) levels in obese rats. Pirinixic acid also causes increased SIRT1 activity in Sham and ischemia-reperfusion (IR) group, but shows no effects on SIRT3 protein expression. Pirinixic acid enhances NAD⁺, and ATP levels, and prevents endoplasmic reticulum stress (ERS) in rats^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 50892-23-4
Appearance Solid
Molecular Weight 323.80
Formula C₁₄H₁₄ClN₃O₂S
Color White to off-white
SMILES

O=C(O)CSC1=NC(NC2=CC=CC(C)=C2C)=CC(Cl)=N1
Synonyms

Wy-14643
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (38)

All IFRT-PCR2D/3D Cell Culture and DifferentiationIHC

Sort by:

Journal Impact Factor

Cell Metab

The enedioic acid analog 326E alleviates metabolic dysfunction-associated steatohepatitis via dual targeting at ACLY and PPARα. [Abstract]

2025 Oct 22:S1550-4131(25)00396-1. PMID: 41130202
Cell Stem Cell

Hepatic cytochrome P450 8B1 and cholic acid potentiate intestinal epithelial injury in colitis by suppressing intestinal stem cell renewal. [Abstract]

2022 Sep 1;29(9):1366-1381.e9. PMID: 36055192

Pirinixic acid purchased from MedChemExpress. Usage Cited in: Cell Stem Cell. 2022 Sep 1;29(9):1366-1381.e9. [Abstract]

Crypts isolated from Lgr5-EGFP-IRES-creERT2 mice were cultured with CA together with/without 100 μM WY14643/ 10 μM Pioglitazone/ 1 μM GW501516 for 6 days. Representative staining pattern of Lgr5⁺ cells.

Pirinixic acid purchased from MedChemExpress. Usage Cited in: Cell Stem Cell. 2022 Sep 1;29(9):1366-1381.e9. [Abstract]

Crypts isolated from Lgr5-EGFP-IRES-creERT2 mice were cultured with 50 μM CA together with/without 100 μM WY14643 for 6 days. The mRNA level of a specified gene.

Pirinixic acid purchased from MedChemExpress. Usage Cited in: Cell Stem Cell. 2022 Sep 1;29(9):1366-1381.e9. [Abstract]

Crypts isolated from Lgr5-EGFP-IRES-creERT2 mice were cultured with 50 μM CA together with/without 100 μM for 6 days. Representative images analysis of organoid budding.

Pirinixic acid purchased from MedChemExpress. Usage Cited in: Cell Stem Cell. 2022 Sep 1;29(9):1366-1381.e9. [Abstract]

WY14643 (1 mg/kg; i.g.). Colitic WT mice were administered with vehicle or WY14643. Representative H&E staining images of intestinal segments.
Theranostics

Activation of N-methyl-D-aspartate receptor regulates insulin sensitivity and lipid metabolism. [Abstract]

2021 Jan 1;11(5):2247-2262. PMID: 33500723
Theranostics

NIK links inflammation to hepatic steatosis by suppressing PPARα in alcoholic liver disease. [Abstract]

2020 Feb 18;10(8):3579-3593. PMID: 32206109
J Exp Clin Cancer Res

GSTK1 suppresses HCC aggravation via L-carnitine metabolism by PGAM5/DRP1 complex-mediated mitochondrial quality control. [Abstract]

2025 Nov 24;45(1):1. PMID: 41276823
Adv Sci (Weinh)

Reprogramming of Fatty Acid Metabolism via PPARα-Orchestrated FADS2 in Keratinocytes Modulates Skin Inflammation in Psoriasis. [Abstract]

2025 Aug 29:e17049. PMID: 40878384

Pirinixic acid purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Aug 29:e17049. [Abstract]

RT-qPCR analysis of FADS2 and indicated genes in HaCaT cells pretreated with 50 μM WY14643 or DMSO for 21 h, followed by PBS or M5 stimulation for 3 h.
Phytomedicine

2025 Dec 28.
Phytomedicine

Calycosin alleviates myocardial fibrosis after myocardial infarction by restoring fatty acid metabolism homeostasis through inhibiting FAP. [Abstract]

2025 Sep:145:157045. PMID: 40627929
Phytomedicine

Poncirin ameliorates alcoholic liver injury by regulating lipid metabolism and inflammatory response in a PPARα dependent manner. [Abstract]

2025 May:140:156598. PMID: 40056635
EBioMedicine

Peripheral amyloid-β clearance mediates cognitive impairment in non-alcoholic fatty liver disease. [Abstract]

2024 Apr:102:105079. PMID: 38507874
J Hazard Mater

Long-term low-dose exposure to 9-chlorophenanthrene induces liver lipid accumulation via disrupting circadian rhythm. [Abstract]

2025 Sep 5:495:139145. PMID: 40628211
ACS Environ Au

Machine Learning-Assisted Recognition of Environmental Sulfur-Containing Chemicals in Nontargeted Mass Spectrometry Analysis of Inadequate Mass Resolution. [Abstract]

2025 Aug 5;5(6):573-582. PMID: 41277996
Int J Biol Macromol

Reticuline isomerase AKR1B1 with aldo-keto reductase activity and detoxification function from the insect Blaps rhynchopetera. [Abstract]

2026 Mar:352:151224. PMID: 41791543
Cell Prolif

Targeting Egfr-Mediated Cell Proliferation and Lipid Metabolism Separation Effectively Accelerate Liver Regeneration. [Abstract]

2026 Apr 22:e70214. PMID: 42019507
Environ Pollut

Mitochondria damage in ambient particulate matter induced cardiotoxicity: Roles of PPAR alpha/PGC-1 alpha signaling. [Abstract]

2021 Nov 1:288:117792. PMID: 34280742
Ecotoxicol Environ Saf

Real ambient particulate matter-induced lipid metabolism disorder: Roles of peroxisome proliferators-activated receptor alpha. [Abstract]

2022 Feb:231:113173. PMID: 35007830
Commun Biol

Cholecystectomy inhibits fasting hepatic fatty acid oxidation in mice. [Abstract]

2026 Feb 2;9(1):349. PMID: 41629390
Mar Drugs

Novel PPAR-γ Agonist from the Soft Coral Sarcophyton crassocaule: Modulating Glucose Uptake and Lipid Droplet Formation. [Abstract]

2025 Nov 24;23(12):450. PMID: 41440884
Acta Physiol

SARM1 promotes the neuroinflammation and demyelination through IGFBP2/NF-κB pathway in experimental autoimmune encephalomyelitis mice. [Abstract]

2023 Jun;238(2):e13974. PMID: 37186158
Chem Biol Interact

New insights into Lambda-cyhalothrin-induced lipid metabolism disorder in liver: Crosstalk between oxidative stress and PPARα signaling pathway. [Abstract]

2026 Jan 25:424:111872. PMID: 41386472
Molecules

Identification of New Polyacetylenes from Dendropanax morbifera with PPAR-α Activity Study. [Abstract]

2024 Dec 16;29(24):5942. PMID: 39770031
Biochim Biophys Acta Mol Basis Dis

USP47 alleviates metabolic-associated fatty liver disease by activating the PPARα signaling pathway through the stabilization of SIRT1. [Abstract]

2026 Apr 1;1872(5):168232. PMID: 41930505
Pestic Biochem Physiol

Polystyrene-microplastics and Emamectin Benzoate co-exposure induced lipid remodeling by suppressing PPARα signals to drive ACSL4-dependent ferroptosis and carp splenic injury. [Abstract]

2025 May:210:106396. PMID: 40262874
Cell Signal

HDAC2 promotes colorectal tumorigenesis by triggering dysregulation of lipid metabolism through YAP1. [Abstract]

2025 Apr:128:111627. PMID: 39875048
J Cell Mol Med

Interfering with mitochondrial dynamics sensitizes glioblastoma multiforme to temozolomide chemotherapy. [Abstract]

2022 Feb;26(3):893-912. PMID: 34964241
J Inflamm Res

The Key Molecular Mechanisms of Sini Decoction Plus Ginseng Soup to Rescue Acute Liver Failure: Regulating PPARα to Reduce Hepatocyte Necroptosis?. [Abstract]

2022 Aug 22;15:4763-4784. PMID: 36032938
iScience

Mof plays distinct roles in hepatic lipid metabolism under healthy or non-alcoholic fatty liver conditions. [Abstract]

2023 Nov 14;26(12):108446. PMID: 38034359
BMC Cancer

PPARα ligand, AVE8134, and cyclooxygenase inhibitor therapy synergistically suppress lung cancer growth and metastasis. [Abstract]

2019 Dec 2;19(1):1166. PMID: 31791289
Cytokine

The LA-NF-κB-ILC2 axis exacerbates intestinal milk protein allergy in mice by promoting ILC2 activation. [Abstract]

2026 May:201:157135. PMID: 41780286
Toxicol Appl Pharmacol

Liquidambaric acid inhibits the proliferation of hepatocellular carcinoma cells by targeting PPARα-RXRα to down-regulate fatty acid metabolism. [Abstract]

2024 Sep:490:117042. PMID: 39067772
Thromb Res

WY-14643, a novel antiplatelet and antithrombotic agent targeting the GPIbα receptor. [Abstract]

2024 Jun:238:41-51. PMID: 38669962
PPAR Res

Hydroxychloroquine Potentiates Apoptosis Induced by PPAR α Antagonist in 786-O Clear Cell Renal Cell Carcinoma Cells Associated with Inhibiting Autophagy. [Abstract]

2021 Apr 19:2021:6631605. PMID: 33959154
Res Sq

2026 Jun 5.
Res Sq

2026 May 3.
bioRxiv

2025 April 10.
bioRxiv

2025 January 22.
Biomed Pharmacother

PIEZO1 as a new target for hyperglycemic stress-induced neuropathic injury: The potential therapeutic role of bezafibrate. [Abstract]

2024 Jul:176:116837. PMID: 38815290
Heliyon

Air-ventilated normothermic machine perfusion alleviates hepatic injury from DCD rat through CYP1A2. [Abstract]

2023 Aug 19;9(8):e19150. PMID: 37654459

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (308.83 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.0883 mL

15.4416 mL

30.8833 mL

5 mM

0.6177 mL

3.0883 mL

6.1767 mL

10 mM

0.3088 mL

1.5442 mL

3.0883 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: 10 mg/mL (30.88 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 10 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (100.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (6.42 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (6.42 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocol

Cell Assay^[2]

Synovial fibroblasts are treated with LPS (100 μg/mL) in the presence or absence of Pirinixic acid. PPAR-α siRNA-transfected cells are also treated with LPS (100 μg/mL) together with Pirinixic acid. After stimulation, the production of NO is determined using Griess reagents. Briefly, 300 μL of supernatant is mixed with 100 μL of Griess reagent and 2.6 mL of deionized water. The mixture is incubated for 30 min at room temperature, and the absorbance at 548 nm is measured. The concentrations of NO in the supernatants are calculated from a standard curve^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[2]

Synovial fibroblasts are treated with LPS (100 μg/mL) in the presence or absence of Wy-14643. PPAR-α siRNA-transfected cells are also treated with LPS (100 μg/mL) together with Wy-14643. After stimulation, the production of NO is determined using Griess reagents. Briefly, 300 μL of supernatant is mixed with 100 μL of Griess reagent and 2.6 mL of deionized water. The mixture is incubated for 30 min at room temperature, and the absorbance at 548 nm is measured. The concentrations of NO in the supernatants are calculated from a standard curve^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (279 KB)
SDS (419 KB)
- English - EN (419 KB)
- Français - FR (419 KB)
- Deutsch - DE (419 KB)
- Norwegian - NO (419 KB)
- Español - ES (419 KB)
- Swedish - SV (419 KB)
- Italian - IT (419 KB)
- Korean - KR (419 KB)
- Portuguese - PT (419 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Willson TM, et al. The PPARs: from orphan receptors to drug discovery. J Med Chem. 2000 Feb 24;43(4):527-50. [Content Brief]

[2]. Huang D, et al. PPAR-α Agonist WY-14643 Inhibits LPS-Induced Inflammation in Synovial Fibroblasts via NF-kB Pathway. J Mol Neurosci. 2016 Aug;59(4):544-53. [Content Brief]

[3]. Pantazi E, et al. PPARα Agonist WY-14643 Induces SIRT1 Activity in Rat Fatty Liver Ischemia-Reperfusion Injury. Biomed Res Int. 2015;2015:894679. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.0883 mL	15.4416 mL	30.8833 mL	77.2082 mL
	5 mM	0.6177 mL	3.0883 mL	6.1767 mL	15.4416 mL
	10 mM	0.3088 mL	1.5442 mL	3.0883 mL	7.7208 mL
	15 mM	0.2059 mL	1.0294 mL	2.0589 mL	5.1472 mL
	20 mM	0.1544 mL	0.7721 mL	1.5442 mL	3.8604 mL
	25 mM	0.1235 mL	0.6177 mL	1.2353 mL	3.0883 mL
	30 mM	0.1029 mL	0.5147 mL	1.0294 mL	2.5736 mL
	40 mM	0.0772 mL	0.3860 mL	0.7721 mL	1.9302 mL
	50 mM	0.0618 mL	0.3088 mL	0.6177 mL	1.5442 mL
	60 mM	0.0515 mL	0.2574 mL	0.5147 mL	1.2868 mL
	80 mM	0.0386 mL	0.1930 mL	0.3860 mL	0.9651 mL
	100 mM	0.0309 mL	0.1544 mL	0.3088 mL	0.7721 mL

Keywords

Pirinixic acid

38 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Pirinixic acid

Bioactive Compound Library Max

Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Cell Cycle/DNA Damage Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Covalent Screening Library

Ferroptosis Compound Library

Endoplasmic Reticulum Stress Compound Library

Anti-Obesity Compound Library

Transcription Factor-Targeted Library

Lipid Metabolism Compound Library

Tumorigenesis-Related Compound Library

Antidepressant Compound Library

Human Metabolite Library

Nuclear Receptor Compound Library

Osteogenesis Compound Library

Cancer Stem Cells Compound Library

Mitochondrial Protection Compound Library

Metabolic Enzyme Compound Library

Mitochondrial Toxicity Compound Library

Highly Selective Activators Library

Multi-Target Compound Library

MCE Bioactive Compound Library

Covalent Screening Library Plus

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) Pirinixic acid

All PPAR Isoforms

Biological Activity

Chemical Information

Publications (38)

Solvent & Solubility

Protocol

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Pirinixic acid Related Classifications

HY-16995 Related Classifications